ORGO · NASDAQ
Organogenesis Holdings Inc.
$0.79 -0.08 (-8.95%)
Company overview
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produces a spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, and cytokines; NuShield, a wound covering tissue that includes both amnion and chorion membranes with the spongy/intermediate layer intact; PuraPly, an antimicrobial barrier that enables conformability and fluid drainage; and Novachor, an amniotic membrane wound covering in which viable cells, growth factor…
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Exchange
- NASDAQ
- Market cap
- $102M
- Employees
- 869
- Headquarters
- Canton, MA
- Website
- organogenesis.com
- CEO
- Gary S. Gillheeney
- Listed
- January 5, 2017
- P/E
- -5.40
- Dividend yield
- 0.00%
Company financials
- Revenue
- $514M
- Gross profit
- $362M
- Operating income
- $11M
- EBITDA
- $44M
- Net income
- -$284,000
- EPS
- -$0.15
- Total assets
- $520M
- Total debt
- $70.9M
- Gross margin
- 70.41%
- Net margin
- -0.06%
- Earnings yield
- -18.51%
No geographic segmentation.
Showing FY 2025
ORGO
1D
NASDAQ
O0.85H0.91L0.83C0.87+0.04 (+4.19%)Vol738.13K
News